Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000902664-25-002308
Filing Date
2025-05-14
Accepted
2025-05-14 08:41:27
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 8501
2 EXHIBIT 99.1: JOINT FILING AGREEMENT p25-0887exhibit99_1.htm EX-99.1 4261
  Complete submission text file 0000902664-25-002308.txt   14464
Mailing Address 202 CARNEGIE CENTER SUITE 301 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 301 PRINCETON NJ 08540 646-885-8505
Y-mAbs Therapeutics, Inc. (Subject) CIK: 0001722964 (see all company filings)

EIN.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-90649 | Film No.: 25942923
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 780 THIRD AVENUE 30TH FLOOR NEW YORK NY 10017
Business Address 780 THIRD AVENUE 30TH FLOOR NEW YORK NY 10017 718-570-6018
Caligan Partners LP (Filed by) CIK: 0001727492 (see all company filings)

EIN.: 822603419 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G